

CRR
JOURNAL
OF CARDIORESPIRATORY RESEARCH

ISSN 2181-0974
DOI 10.26739/2181-0974
Impact Factor SJIF 2022: 5.937

Journal of

**CARDIORESPIRATORY
RESEARCH**



Volume 7, Issue 2/3

2026

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ
РЕСПУБЛИКИ УЗБЕКИСТАН

Журнал кардиореспираторных исследований

JOURNAL OF CARDIORESPIRATORY RESEARCH

Главный редактор: Э.Н.ТАШКЕНБАЕВА

Учредитель:

Самаркандский государственный
медицинский университет

Tadqiqot.uz

Ежеквартальный
научно–практический
журнал

ISSN: 2181-0974
DOI: 10.26739/2181-0974



№ 2/3
2026

Главный редактор:

Ташкенбаева Элеонора Негматовна

доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней и кардиологии №2 Самаркандского Государственного медицинского университета, председатель Ассоциации терапевтов Самаркандской области.
<https://orcid.org/0000-0001-5705-4972>

Заместитель главного редактора:

Хайбулина Зарина Руслановна

*доктор медицинских наук, руководитель отдела биохимии с группой микробиологии
ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0002-9942-2910>*

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ:

Аляви Анис Лютфуллаевич

академик АН РУз, доктор медицинских наук, профессор, Председатель Ассоциации Терапевтов Узбекистана, Советник директора Республиканского специализированного научно-практического центра терапии и медицинской реабилитации (Ташкент)
<https://orcid.org/0000-0002-0933-4993>

Бокерия Лео Антонович

академик РАН, доктор медицинских наук, профессор, Президент научного центра сердечно-сосудистой хирургии им. А.Н. Бакулева (Москва), <https://orcid.org/0000-0002-6180-2619>

Курбанов Равшанбек Давлетович

академик АН РУз, доктор медицинских наук, профессор, Советник директора Республиканского специализированного научно-практического медицинского центра кардиологии (Ташкент), <https://orcid.org/0000-0001-7309-2071>

Шкляев Алексей Евгеньевич

д.м.н., профессор, ректор Федерального государственного бюджетного образовательного учреждения высшего образования «Ижевская государственная медицинская академия» Министерства здравоохранения Российской Федерации

Michał Tendera

профессор кафедры кардиологии Верхнесилезского кардиологического центра, Силезский медицинский университет в Катовице, Польша (Польша)
<https://orcid.org/0000-0002-0812-6113>

Покушалов Евгений Анатольевич

доктор медицинских наук, профессор, заместитель генерального директора по науке и развитию сети клиник «Центр новых медицинских технологий» (ЦНМТ), (Новосибирск), <https://orcid.org/0000-0002-2560-5167>

Зуфаров Миржамол Мирумарович

доктор медицинских наук, профессор, руководитель отдела ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0003-4822-3193>

Акилов Хабибулла Атауллаевич

доктор медицинских наук, профессор, Директор Центра развития профессиональной квалификации медицинских работников (Ташкент)

Насирова Зарина Акбаровна

DSc, доцент кафедры внутренних болезней и кардиологии №2 Самаркандского Государственного Медицинского университета (ответственный секретарь) ORCID: 0000-0002-8722-0393 (ответственный секретарь)

Ризаев Жасур Алимджанович

доктор медицинских наук, профессор, Ректор Самаркандского государственного медицинского университета, <https://orcid.org/0000-0001-5468-9403>

Зиядуллаев Шухрат Худойбердиевич

доктор медицинских наук, профессор, первый заместитель директора по академической деятельности Самаркандского филиала Международного Университета Кимё в Ташкенте
<https://orcid.org/0000-0002-9309-3933>

Джан Ковак

Профессор, председатель Совета Европейского общества кардиологов по инсульту, руководитель специализированной кардиологии, заведующий отделением кардиологии, кардио- и торакальной хирургии, консультант-кардиолог, больница Гленфилд, Лестер (Великобритания)

Сергио Бернардини

Профессор клинической биохимии и клинической молекулярной биологии, главный врач отдела лабораторной медицины, больница Университета Тор Вергата (Рим, Италия)

Ливерко Ирина Владимировна

доктор медицинских наук, профессор, заместитель директора по науке Республиканского специализированного научно-практического медицинского центра фтизиатрии и пульмонологии Республики Узбекистан (Ташкент)
<https://orcid.org/0000-0003-0059-9183>

Цурко Владимир Викторович

доктор медицинских наук, профессор Первого Московского государственного медицинского университета им. И.М. Сеченова (Москва)
<https://orcid.org/0000-0001-8040-3704>

Тригулова Ранса Хусановна

Доктор медицинских наук, руководитель лаборатории превентивной кардиологии, ведущий научный сотрудник лаборатории ИБС и атеросклероза. Республиканский специализированный научно-практический медицинский центр кардиологии (Ташкент)
ORCID- 0000-0003-4339-0670

Тураев Феруз Фатхуллаевич

доктор медицинских наук, Директор Республиканского специализированного научно-практического медицинского центра эндокринологии имени академика Ю.Г. Туракулова

Bosh muharrir:

Tashkenbayeva Eleonora Negmatovna

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini mudiri, Samarqand viloyati vrachlar uyushmasi raisi
<https://orsid.org/0000-0001-5705-4972>

Bosh muharrir o'rinbosari:

Xaibulina Zarina Ruslanovna

tibbiyot fanlari doktori, "akad V. Vohidov nomidagi RIJM davlat institutining mikrobiologiya guruhi bilan biokimyo kafedrasini mudiri" <https://orcid.org/0000-0002-9942-2910>

TAHRIRIYAT A'ZOLARI:

Alyavi Anis Lyutfullayevich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, O'zbekiston Terapevtlar uyushmasi raisi, Respublika ixtisoslashtirilgan ilmiy va amaliy tibbiy terapiya markazi va tibbiy reabilitatsiya direktori maslahatchisi (Toshkent), <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Rossiya fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, A.N. Bakuleva nomidagi yurak-qon tomir jarrohligi ilmiy markazi prezidenti (Moskva)
<https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davlatovich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazining direktor maslahatchisi (Toshkent)
<https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Tibbiyot fanlari doktori, professor, Rossiya Federatsiyasi Sog'liqni saqlash vazirligining "Izhevsk davlat tibbiyot akademiyasi" Federal davlat byudjeti oliy ta'lim muassasasi rektori

Mixal Tendera

Katovitsadagi Sileziya Tibbiyot Universiteti, Yuqori Sileziya Kardiologiya Markazi kardiologiya kafedrasini professori (Polsha)
<https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeniy Anatolevich

tibbiyot fanlari doktori, professor, "Yangi tibbiy texnologiyalar markazi" (YTTM) klinik tarmog'ining ilmiy ishlar va rivojlanish bo'yicha bosh direktorining o'rinbosari (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Zufarov Mirjamol Mirumarovich

tibbiyot fanlari doktori, professor, "akad V. Vohidov nomidagi RIJM davlat muassasasi" bo'limi boshlig'i"
<https://orcid.org/0000-0003-4822-3193>

Akilov Xabibulla Ataulayevich

tibbiyot fanlari doktori, professor, Tibbiyot xodimlarining kasbiy malakasini oshirish markazi direktori (Toshkent)

Nasirova Zarina Akbarovna

Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini dotsenti, DSc (mas'ul kotib) ORCID: 0000-0002-8722-0393 (mas'ul kotib)

Rizayev Jasur Alimjanovich

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti rektori
<https://orcid.org/0000-0001-5468-9403>

Ziyadullayev Shuxrat Xudoyberdiyevich

tibbiyot fanlari doktori, professor, Toshkent shahridagi Kimyo xalqaro universitetining Samarqand filiali direktorining akademik faoliyat bo'yicha birinchi o'rinbosari (Toshkent)
<https://orcid.org/0000-0002-9309-3933>

Jan Kovak

Yevropa kardiologiya jamiyati insult kengashi raisi, 2017 yildan buyon ixtisoslashtirilgan kardiologiya kafedrasini rahbari, kardiologiya, yurak va torakal jarrohlik kafedrasini mudiri, maslahatchi kardiolog Glenfild kasalxonasi, Lester (Buyuk Britaniya)

Sergio Bernardini

Klinik biokimyo va klinik molekulyar biologiya bo'yicha professor - Laboratoriya tibbiyoti bo'limi bosh shifokori – Tor Vergata universiteti kasalxonasi (Rim-Italiya)

Liverko Irina Vladimirovna

tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan fiziologiya va pulmonologiya ilmiy-amaliy tibbiyot markazining ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent)
<https://orcid.org/0000-0003-0059-9183>

Surko Vladimir Viktorovich

tibbiyot fanlari doktori, professori I.M. Sechenov nomidagi Birinchi Moskva Davlat tibbiyot universiteti (Moskva)
<https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Xusainovna

Tibbiyot fanlari doktori, Profilaktik kardiologiya laboratoriyasi mudiri, YuIK va ateroskleroz laboratoriyasining yetakchi ilmiy xodimi. Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi (Toshkent)
ORCID- 0000-0003-4339-0670

Turayev Feruz Fatxullayevich

tibbiyot fanlari doktori, akademik Y.X.To'raqulov nomidagi Respublika ixtisoslashtirilgan endokrinologiya ilmiy amaliy tibbiyot markazi direktori
<https://orcid.org/0000-0002-1321-4732>

Chief Editor:

Tashkenbaeva Eleonora Negmatovna

Doctor of Medical Sciences, professor, Head of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University, Chairman of the Association of Physicians of the Samarkand Region. <https://orsid.org/0000-0001-5705-4972>

Deputy Chief Editor:

Xaibulina Zarina Ruslanovna

Doctor of Medical Sciences, Head of the Department of Biochemistry with the Microbiology Group of the State Institution "RSSC named after acad. V. Vakhidov", <https://orcid.org/0000-0002-9942-2910>

MEMBERS OF THE EDITORIAL BOARD:

Alyavi Anis Lutfullaevich

Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Chairman of the Association of Physicians of Uzbekistan, Advisor to the Director of the Republican Specialized Scientific - Practical Center of Therapy and Medical Rehabilitation (Tashkent) <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, President of the Scientific Center for Cardiovascular Surgery named after A.N. Bakuleva (Moscow) <https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davletovich

Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Advisor to the Director Republican Specialized Scientific and Practical Medical Center of Cardiology, (Tashkent) <https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Doctor of Medical Sciences, Professor, Rector of the Federal State Budgetary Educational Institution of Higher Education "Izhevsk State Medical Academy" of the Ministry of Health of the Russian Federation

Michal Tendera

Professor of the Department of Cardiology, Upper Silesian Cardiology Center, Silesian Medical University in Katowice, Poland (Poland) <https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeny Anatolyevich

Doctor of Medical Sciences, Professor, Deputy Director General for Science and Development of the Clinic Network "Center for New Medical Technologies" (CNMT), (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Akilov Xabibulla Ataulaevich

Doctor of Medical Sciences, Professor, Center for the development of professional qualifications of medical workers (Tashkent)

Nasyrova Zarina Akbarovna

DSc, Associate Professor of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University (Executive Secretary) ORCID: 0000-0002-8722-0393 (Executive Secretary)

Rizaev Jasur Alimjanovich

Doctor of Medical Sciences, Professor, Rector of the Samarkand State Medical University <https://orcid.org/0000-0001-5468-9403>

Ziyadullaev Shuhrat Khudoyberdievich

Doctor of Medical Sciences, Professor, Deputy Director for Scientific Doctor of Medical Sciences, Professor, First Deputy Director for Academic Affairs of the Samarkand branch of Kimyo International University in Tashkent <https://orcid.org/0000-0002-9309-3933>

Jan Kovac

Professor Chairman, European Society of Cardiology Council for Stroke, Lead of Specialised Cardiology, Head of Cardiology, Cardiac and Thoracic Surgery, Consultant Cardiologist, Glenfield Hospital, Leicester (United Kingdom)

Sergio Bernardini

Full Professor in Clinical Biochemistry and Clinical Molecular Biology -Head Physician of the Laboratory Medicine Unit- University of Tor Vergata Hospital (Rome-Italy)

Liverko Irina Vladimirovna

Doctor of Medical Sciences, Professor, Deputy Director for Science of the Republican Specialized Scientific and Practical Medical Center for Phthiology and Pulmonology of the Republic of Uzbekistan (Tashkent) <https://orcid.org/0000-0003-0059-9183>

Zufarov Mirjamol Mirumarovich

Doctor of Medical Sciences, Professor, Head of the Department of the State Institution "RSNPMTSH named after acad. V. Vakhidov" <https://orcid.org/0000-0003-4822-3193>

Tsurko Vladimir Viktorovich

Doctor of Medical Sciences, professor Of Moscow State Medical University by name I.M. Sechenov (Moscow) <https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Khusainovna

Doctor of Medical Sciences, Head of the Laboratory of Preventive Cardiology, Leading Researcher of the Laboratory of IHD and Atherosclerosis. Republican Specialized Scientific and Practical Medical Center of Cardiology (Tashkent) ORCID- 0000-0003-4339-0670

Turaev Feruz Fatxullaevich

Doctor of Medical Sciences, Director of the Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Yu.G. Turakulova

Алимов Дониёр Анварович
доктор медицинских наук, директор
Республиканского научного центра
экстренной медицинской помощи

Абдуллаев Акбар Хатамович
доктор медицинских наук, главный
научный сотрудник Республиканского
специализированного научно-
практического центра медицинской
терапии и реабилитации
<https://orcid.org/0000-0002-1766-4458>

Агабабян Ирина Рубеновна
кандидат медицинских наук, доцент,
заведующая кафедрой терапии ФПДО,
Самаркандского Государственного
медицинского института

Алиева Нигора Рустамовна
доктор медицинских наук, заведующая
кафедрой Госпитальной педиатрии №1
с основами нетрадиционной медицины
ТашПМИ

Исмаилова Адолат Абдурахимовна
доктор медицинских наук, профессор,
заведующая лабораторией
фундаментальной иммунологии
Института иммунологии геномики
человека АН РУз

Камалов Зайнитдин Сайфутдинович
доктор медицинских наук, профессор,
заведующий лабораторией
иммунорегуляции Института
иммунологии и геномики
человека АН РУз

Каюмов Улугбек Каримович
доктор медицинских наук, профессор,
заведующий кафедрой внутренних
болезней и телемедицины Центра
развития профессиональной
квалификации медицинских работников

Хусинова Шоира Акбаровна
кандидат философских наук, доцент,
заведующая кафедрой общей практики,
семейной медицины ФПДО
Самаркандского Государственного
медицинского института

Шодиколова Гуландом Зикрияевна
д.м.н., профессор, заведующая
кафедрой внутренних болезней № 3
Самаркандского Государственного
Медицинского Института
(Самарканд)
<https://orcid.org/0000-0003-2679-1296>

Doniyorova Farangisbonu Alisher qizi
Toshkent Davlat tibbiyot universiteti
nevrologiya va xalq tabobati kafedrasida
dotsenti, DSc.
<https://orcid.org/0009-0004-4140-4797>

Alimov Doniyor Anvarovich
tibbiyot fanlari doktori, Respublika
shoshilinch tibbiy yordam ilmiy
markazi direktori (Toshkent)

Abdullayev Akbar Xatamovich
tibbiyot fanlari doktori, O'zbekiston
Respublikasi Sog'liqni saqlash
vazirligining "Respublika
ixtisoslashtirilgan terapiya va tibbiy
reabilitatsiya ilmiy-amaliy
tibbiyot markazi" davlat
muassasasi bosh ilmiy xodimi
<https://orcid.org/0000-0002-1766-4458>

Agababayan Irina Rubenovna
tibbiyot fanlari nomzodi, dotsent,
DKTF, terapiya kafedrasida mudiri,
Samarqand davlat tibbiyot instituti

Alieva Nigora Rustamovna
tibbiyot fanlari doktori, 1-sonli
gospital pediatriya kafedrasida mudiri,
ToshPТИ

Ismoilova Adolat Abduraximovna
tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Odam genomikasi
immunologiyasi institutining
fundamental immunologiya
laboratoriyasining mudiri

Kamalov Zaynitdin Sayfutdinovich
tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Immunologiya va
inson genomikasi institutining
Immunogenetika laboratoriyasi mudiri

Qayumov Ulug'bek Karimovich
tibbiyot fanlari doktori, professor,
Tibbiyot xodimlarining kasbiy
malakasini oshirish markazi, ichki
kasalliklar va teletibbiyot kafedrasida
mudiri (Toshkent)

Xusinova Shoira Akbarovna
tibbiyot fanlari nomzodi, dotsent,
Samarqand davlat tibbiyot instituti
DKTF Umumiy amaliyot va oilaviy
tibbiyot kafedrasida mudiri (Samarqand)

Shodiqulova Gulandom Zikriyevna
tibbiyot fanlari doktori, professor,
Samarqand davlat tibbiyot instituti 3-
ichki kasalliklar kafedrasida mudiri
(Samarqand)
<https://orcid.org/0000-0003-2679-1296>

Doniyorova Farangisbonu Alisher kizi
доцент кафедры неврологии и
народной медицины Ташкентского
государственного медицинского
университета, доктор медицинских
наук. <https://orcid.org/0009-0004-4140-4797>

Alimov Doniyor Anvarovich
Doctor of Medical Sciences, Director of
the Republican Scientific Center of
Emergency Medical Care

Abdullaev Akbar Xatamovich
Doctor of Medical Sciences,
Chief Researcher of the State Institution
"Republican Specialized Scientific and
Practical Medical Center for Therapy and
Medical Rehabilitation" of the Ministry of
Health of the Republic of Uzbekistan,
<https://orcid.org/0000-0002-1766-4458>

Agababayan Irina Rubenovna
PhD, Associate Professor, Head of the
Department of Therapy, FAGE,
Samarkand State Medical Institute

Alieva Nigora Rustamovna
Doctor of Medical Sciences, Head of the
Department of Hospital Pediatrics
No. 1 with the basics of alternative
medicine, TashPТИ

Ismailova Adolat Abduraximovna
doctor of Medical Sciences, Professor,
Head of the Laboratory of Fundamental
Immunology of the Institute of
Immunology of Human
Genomics of the Academy of Sciences
of the Republic of Uzbekistan

Kamalov Zaynitdin Sayfutdinovich
doctor of Medical Sciences, Professor,
Head of the Laboratory of
Immunogenetics of the Institute of
Immunology and Human Genomics
of the Academy of Sciences of the
Republic of Uzbekistan

Kayumov Ulugbek Karimovich
Doctor of Medical Sciences, Professor,
Head of the Department of Internal
Diseases and Telemedicine of the Center
for the development of professional
qualifications
of medical workers

Khusinova Shoira Akbarovna
PhD, Associate Professor, Head of the
Department of General Practice,
Family Medicine FAGE of the
Samarkand State Medical Institute

Shodikulova Gulandom Zikriyevna
Doctor of Medical Sciences, professor,
head of the Department of Internal
Diseases N 3 of Samarkand state medical
institute (Samarkand)
<https://orcid.org/0000-0003-2679-1296>

Doniyorova Farangisbonu Alisher kizi
Associate Professor, Department of
Neurology and Traditional Medicine,
Tashkent State Medical University, DSc.
<https://orcid.org/0009-0004-4140-4797>

Халиков Каххор Мирзаевич
кандидат медицинских наук, доцент
заведующий кафедрой биологической
химии Самаркандского
государственного медицинского
университета

Тулабаева Гавхар Миракбаровна
Заведующая кафедрой кардиологии,
Центр развития профессиональной
квалификации медицинских
работников, д.м.н., профессор

**Абдумаджидов Хамидулла
Амануллаевич**

Бухарский государственный
медицинский институт имени Абу
Али ибн Сино. Кафедра «Хирургические
болезни и реанимация». Доктор
медицинских наук, профессор.

Саидов Мақсуд Арифович

к.м.н., директор Самаркандского
областного отделения
Республиканского специализированного
научно-практического медицинского
центра кардиологии (г. Самарканд)

Срождинова Нигора Зайнутдиновна

д.м.н. Заведующая научно-
исследовательской лабораторией
кардиодиабета и метаболических
нарушений РСНПМЦК

Носирова Дилангиз Акбаровна

Ассистент кафедры внутренних
болезней и кардиологии №2
Самаркандского государственного
медицинского университета
(технический секретарь)

Эсанкулов Мухаммад Олимович

Ассистент кафедры внутренних
болезней и кардиологии №2
Самаркандского государственного
медицинского университета
(технический секретарь)

Xalikov Qaxxor Mirzayevich
*Tibbiyot fanlari nomzodi, dotsent
Samarqand davlat tibbiyot universiteti
Biologik kimyo kafedrasini mudiri*

Tulabayeva Gavxar Mirakbarovna
*kardiologiya kafedrasini mudiri, tibbiyot
xodimlarining kasbiy malakasini rivojlantirish
markazi, tibbiyot fanlari doktori, professor*

Abdumadjidov Xamidulla Amanullayevich

*«Abu Ali ibn Sino nomidagi Buxoro davlat
tibbiyot oliygohi» Xirurgiya kasalliklari va
reanimatsiya kafedrasini professori, tibbiyot
fanlari doktori.*

Saidov Maqsud Arifovich

*tibbiyot fanlari nomzodi,
Respublika ixtisoslashgan kardiologiya
ilmiy amaliy tibbiyot markazi Samarqand
viloyat mintaqaviy filiali direktori
(Samarqand)*

Srojidinova Nigora Zaynutdinovna

*t.f.d. Kardiodiabet va metabolik buzilishlar
ilmiy tadqiqot laboratoriyasi mudiri*

Nosirova Dilangiz Akbarovna

*Samarqand davlat tibbiyot universiteti 2-son
ichki kasalliklar va kardiologiya kafedrasini
assistenti (texnik kotib)*

Esankulov Muxammad Olimovich

*Samarqand davlat tibbiyot universiteti 2-son
ichki kasalliklar va kardiologiya kafedrasini
assistenti (texnik kotib), PhD*

Khalikov Kakhor Mirzayevich
*Candidate of Medical Sciences,
Associate Professor, Head of the Department
of Biological Chemistry, Samarkand State
Medical University*

Tulabayeva Gavxar Mirakbarovna
*Head of the Department of Cardiology,
Development Center professional
qualification of medical workers,
MD, professor*

**Abdumadjidov Khamidulla
Amanullayevich**

*“Bukhara state medical institute named
after Abu Ali ibn Sino”. DSc, professor.*

Saidov Maksud Arifovich

*Candidate of Medical Sciences, Director
of the Samarkand Regional Department of
the Republican Specialized Scientific and
Practical Medical Center of Cardiology
(Samarkand)*

Srojidinova Nigora Zaynutdinovna

*DSc, Head of Kardiodiabetes and Metabolic
Disorders Laboratory*

Dilangiz Akbarovna Nosirova,

*Assistant of the Department of Internal
Diseases and Cardiology No. 2, Samarkand
State Medical University (Technical Secretary)*

Esankulov Muhammad Olimovich,

*Assistant of the Department of Internal
Diseases and Cardiology No. 2, Samarkand
State Medical University (Technical Secretary)*

СИСТЕМНЫЕ ЗАБОЛЕВАНИЯ СОЕДИНИТЕЛЬНОЙ ТКАНИ: СОВРЕМЕННЫЕ ПОДХОДЫ

1.	<p>M.Z. Axadova Revmatoid artrit va yurak ishemik kasalligi М.З. Ахадова Ревматоидный артрит и ишемическая болезнь сердца M.Z. Axadova Rheumatoid arthritis and heart ischemic disease.....</p>	11
2.	<p>И.А. Ахмедов, Г.З. Шодикүлова Оценка клинической и иммунологической эффективности применения генно-инженерных биологических препаратов с использованием инфузионной помпы при ревматических заболеваниях I.A. Akhmedov, G.Z. Shodikulova Evaluation of the clinical and immunological effectiveness of genetically engineered biological drugs administered via an infusion pump in rheumatic diseases I.A. Axmedov, G.Z. Shodikulova Revmatik kasalliklarda infuzion pompa yordamida gen-injener biologik dori vositalarini qo'llashning klinik va immunologik samaradorligini baholash.....</p>	14
3.	<p>З.Б. Бабамурадова, Н.Н. Шавазӣ Особенности течения антифосфолипидного синдрома у беременных женщин Z.B. Babamuradova, N.N. Shavazi Features of the course of antiphospholipid syndrome in pregnant women Z.B. Babamuradova, N.N. Shavazi Homilador ayollarda antifosfolipid sindromning kechish xususiyatlari.....</p>	19
4.	<p>Л.С. Батырбекова, С.А. Серикова, З.А. Базарбаева, О.В. Казимирова, А.Р. Бейсенаева, З.А. Кенжетаетаева, Б.М. Телегенова, Б.Д. Жапаркул Роль искусственного интеллекта в современной медицине (обзор литературы) L.S. Batyrbekova, S.A. Serikova, Z.A. Bazarbayeva, O.V. Kazimirova, A.R. Beisenayeva, Z.A. Kenzhetayeva, B.M. Telegenova, B.D. Zhaparkul The role of artificial intelligence in modern medicine (literature review) L.S. Batyrbekova, S.A. Serikova, Z.A. Bazarbayeva, O.V. Kazimirova, A.R. Beysenayeva, Z.A. Kenzhetayeva, B.M. Telegenova, B.D. Japarkul Zamonaviy tibbiyotda sun'iy intellektning roli (adabiyotlar sharhi).....</p>	22
5.	<p>Д.Х.Бердиев; С.Х.Ярмухамедова Сравнительная оценка влияния фебуксостата и аллопуринола на показатели эндотелиальной дисфункции у пациентов с коморбидным течением подагры и артериальной гипертензии D.H. Berdiev; S.X. Yarmukhamedova Comparative evaluation of the effect of febusostat and allopurinol on endothelial dysfunction parameters in patients with comorbid gout and arterial hypertension D.H. Berdiyev; S.X. Yarmuxamedova Podagra va arterial gipertenziya komorbid kechgan bemorlarda febuxsostat va allopurinolning endotelial disfunktsiya ko'rsatkichlariga ta'sirini qiyosiy baholash.....</p>	26
6.	<p>Вохидов Ж. Ж., Рўзманова Г.И. Псориатический артрит и сердечно-сосудистые заболевания: многогранные коморбидные состояния и интегрированный подход к лечению Vokhidov J.J., Ruzmanova G.I Cardiovascular disease in psoriatic arthritis: multidimensional comorbidities and an integrated treatment approach Vohidov J.J., Ro'zmanova G. I. Psoriatik artritda yurak-qon tomir kasalliklari: ko'p qirrali qo'shma kasalliklar va integratsiyalashgan davolash yondashuvi.....</p>	31
7.	<p>Г.Д. Клеблеева, У.А. Ташкенбаева, Г.З. Шодикүлова Особенности диагностики и лечения аллергических васкулитов (кожно-сосудистых) на фоне коморбидных состояний G.D. Klebleyeva, U.A. Tashkenbaeva, G.Z. Shodikulova Diagnosis and treatment of allergic vasculitis (cutaneous and vascular) associated with comorbid conditions G.D. Klebleeva, U.A. Tashkenbaeva, G.Z. Shodikulova Komorbid holatlar bilan bog'liq allergik vaskulit (teri va qon tomir) diagnostikasi va davolash.....</p>	36
8.	<p>Г.З. Мухитдинова Волчаночный нефрит: эпидемиология прогрессирования и современные стратегии доказательной терапии G.Z. Mukhitdinova Lupus nephritis: epidemiology of progression and modern evidence-based therapy strategies G.Z. Muxitdinova Volchanochniy nefrit: kasallik progressiyasining epidemiologiyasi va zamonaviy dalillarga asoslangan terapiya strategiyalari.....</p>	41

9.	<p>Д.А.Набиева, С.Б.Мамасиддикова, А.А.Мамасиддиков, А.Т. Шаропова. Особенности течения беременности и факторы риска тромбоцитопении у пациенток с системной красной волчанкой D.A.Nabieva, S.B.Mamasiddikova, A.A. Mamasiddikov, A.T. Sharopova. Features of pregnancy course and risk factors for thrombocytopenia in patients with systemic lupus erythematosus D.A.Nabiyeva, S.B.Mamasiddiqova, A.A. Mamasiddiqov, A.T. Sharopova.. Tizimli qizil yuguruk bilan ogʻrigan bemorlarda homiladorlik kechishining xususiyatlari va trombositopeniya rivojlanish xavf omillari.....</p>	47
10.	<p>Б.У. Низомов, К.А. Исламова Роль активности системы комплемента в формировании системной красной волчанки B.U. Nizomov, K.A. Islamova The role of complement system activity in the development of systemic lupus erythematosus B.U. Nizomov, K.A. Islamova Komplement tizimi faolligining tizimli qizil yugurik shakllanishidagi oʻrni.....</p>	51
11.	<p>М.С. Равшанова, Х.И. Ибрагимов, Ш.Х. Зиядуллаев Клиническая эффективность комбинированной терапии биологическими и синтетическими БПВП при ревматоидном артрите M.S. Ravshanova, Kh.I. Ibragimov, Sh.X. Ziyadullayev Clinical effectiveness of biologic and synthetic DMARD combination therapy in rheumatoid arthritis M.S. Ravshanova, X.I. Ibragimov, Sh.X. Ziyadullayev Revmatik artritda biologik va sintetik DMARD'lar kombinatsiyali terapiyasining klinik samaradorligi.....</p>	56
12.	<p>М.С. Равшанова, М.А. Эшбеков, Х.И. Ибрагимов, Ш.Х. Зиядуллаев Современные иммунопатогенетические механизмы ревматоидного артрита M.S. Ravshanova, M.A. Eshbekov, Kh.I. Ibragimov, Sh.X. Ziyadullaev Modern immunopathogenetic mechanisms of rheumatoid arthritis M.S. Ravshanova, M.A. Eshbekov, X.I. Ibragimov, Sh.X. Ziyadullaev Revmatik artritning zamonaviy immunopatogenetik mexanizmlari.....</p>	60
13.	<p>Д.Р. Таиров, Д.Х. Бердиев Клинико-иммунологические и генетические особенности кардиоренальных поражений и метаболического синдрома при подагре и гиперурикемии D.R. Tairov, D.H. Berdiyev Clinical, immunological and genetic characteristics of cardiorenal lesions and metabolic syndrome in gout and hyperuricemia D.R. Tairov, D.H. Berdiyev Podagra va giperurikemiya holatida kardiorrenal zararlanishlar hamda metabolik sindromning klinik, immunologik va genetik xususiyatlari.....</p>	67
14.	<p>З.К. Таирова, Г.З. Шодиккулова Современные этиологические аспекты и стратификация факторов риска развития остеопороза Z.K. Tairova, G.Z. Shodikulova Modern etiological aspects and stratification of risk factors for osteoporosis development Z.K. Tairova, G.Z. Shodiqulova Osteoporoz rivojlanishining zamonaviy etiologik jihatlari va xavf omillarining stratifikatsiyasi.....</p>	72
15.	<p>М. М. Туркманов Современное состояние проблемы остеоартроза у пациентов с недифференцированной дисплазией соединительной ткани M. M. Turkmanov Differensiyalanmagan biriktiruvchi to'qima displaziyasi bo'lgan bemorlarda osteoartroz muammosining zamonaviy holati M. M. Turkmanov Current state of the problem of osteoarthritis in patients with undifferentiated connective tissue dysplasia.....</p>	78
16.	<p>Хасанов О.Г., Хазратов Н.М Микробиота кишечника и ревматоидный артрит: обзор литературы Khasanov O.G., Khazratov N.M. Gut microbiota and rheumatoid arthritis: a literature review Xasanov O.G., Xazratov N.M Ichak mikrobiotasi va revmatoid artrit: adabiyotlar sharhi.....</p>	82
17.	<p>Хусанов М.У., Эргашова М.М. Системная красная волчанка: эпидемиология, патогенез, диагностика и современные подходы к лечению Khusanov M.U., Ergashova M.M. Systemic lupus erythematosus: epidemiology, pathogenesis, diagnosis and modern treatment approaches Xusanov M.U., Ergashova M.M. Tizimli qizil yuguriq: epidemiologiya, patogenez, tashxis va zamonaviy davolash yondashuvlari.....</p>	88

18.	G.Z. Shodikulova, Sh.N. Sadikova Revmatoid artritda osteoporoz rivojlanish xavfini kompleks kliniko-genetik va instrumental baholash: D vitamini metabolizmi, VDR polimorfizmlari va suyak mineral zichligi parametrlari Г.З. Шодикүлова, Ш.Н. Садикова Комплексная клинко-генетическая и инструментальная оценка риска развития остеопороза при ревматоидном артрите: метаболизм витамина Д, полиморфизмы VDR и параметры минеральной плотности костей	
	G.Z. Shodikulova, Sh.N. Sadikova Comprehensive clinical-genetic and instrumental assessment of the risk of osteoporosis in rheumatoid arthritis: metabolism of vitamin D, VDR polymorphism and parameters of bone mineral density.....	92
19.	Г.З. Шодикүлова, О.Ф. Шамсиев Клинко-патогенетические аспекты развития остеопороза у женщин G.Z. Shodikulova, O.F. Shamsiev Clinical and pathogenetic aspects of osteoporosis development in women G.Z. Shodikulova, O.F. Shamsiyev Ayollarda osteoporoz rivojlanishining klinik-patogenetik jihatlari.....	
	Мирзаев О.В., Нурмаматов Ж.Х. Распространенность и клинко-генетические особенности дисплазии соединительной ткани у узбекского населения Mirzayev O.V., Nurmatov J.Kh. Prevalence and clinical - genetic features of connective tissue dysplasia in the uzbek population Mirzayev O.V., Nurmatov J.X. O‘zbek populyatsiyasida biriktiruvchi to‘qima displaziyasining tarqalishi va kliniko-genetik xususiyatlari.....	96
20.		
		102

**Равшанова М.С.**Самаркандский государственный медицинский университет
Самарканд, Узбекистан**Эшбеков М.А.**Самаркандский государственный медицинский университет
Самарканд, Узбекистан**Ибрагимов Х.И.**Самаркандский государственный медицинский университет
Самарканд, Узбекистан**Зиядуллаев Ш.Х.**Самаркандский государственный медицинский университет
Самарканд, Узбекистан**СОВРЕМЕННЫЕ ИММУНОПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ РЕВМАТОИДНОГО АРТРИТА****For citation:** M.S. Ravshanova, M.A. Eshbekov, Kh.I. Ibragimov, Sh.X. Ziyadullaev. MODERN IMMUNOPATHOGENETIC MECHANISMS OF RHEUMATOID ARTHRITIS. Journal of cardiorespiratory research. 2026, vol 7, issue 2/3.<http://dx.doi.org/10.26739/2181-0974/2026/7/2/3/13>**АННОТАЦИЯ**

Иммунологические изменения, наблюдаемые при ревматоидном артрите, предоставляют важные сведения о механизмах развития и прогрессирования заболевания. Аутоантитела, такие как ревматоидный фактор (РФ) и антитела к циклическому цитруллинированному пептиду (анти-ЦЦП), играют ключевую роль в патогенезе РА, способствуя воспалению и повреждению суставов. Дисрегуляция Т-клеток, особенно провоспалительных субпопуляций, дополнительно усиливает патологический иммунный ответ, наблюдаемый при РА. Иммунологические изменения при РА имеют важное значение для профилактики, ранней диагностики, лечения и прогноза заболевания.

Ключевые слова: ревматоидный артрит, аутоантитела, патогенез, цитокины.**Ravshanova M.S.**Samarkand State Medical University
Samarkand, Uzbekistan**Eshbekov M.A.**Samarkand State Medical University
Samarkand, Uzbekistan**Ibragimov Kh.I.**Samarkand State Medical University
Samarkand, Uzbekistan**Ziyadullaev Sh.Kh.**Samarkand State Medical University
Samarkand, Uzbekistan**MODERN IMMUNOPATHOGENETIC MECHANISMS OF RHEUMATOID ARTHRITIS****ANNOTATION**

The immunological changes observed in RA provide crucial insights into the underlying mechanisms of disease development and progression. Autoantibodies, such as antibodies to rheumatoid factor (RF) and antibodies to cyclic citrullinated peptide (anti-CCP), play a key role in the pathogenesis of RA, contributing to inflammation and joint damage. Dysregulation of T cells, especially pro-inflammatory subpopulations, further contributes to the abnormal immune response seen in RA. Immunological changes observed in RA have important implications for prevention, early diagnosis, treatment and prognosis of the disease.

Key words: Rheumatoid arthritis, autoantibodies, pathogenesis, cytokines.**Ravshanova M.S.**Samarqand davlat tibbiyot universiteti
Samarqand, O'zbekiston

Eshbekov M.A.

Samarqand davlat tibbiyot universiteti
Samarqand, O'zbekiston

Ibragimov Kh.I.

Samarqand davlat tibbiyot universiteti
Samarqand, O'zbekiston

Ziyadullaev Sh.X.

Samarqand davlat tibbiyot universiteti
Samarqand, O'zbekiston

РЕВМАТОИД АРТРИТНИНГ ЗАМОНАВИЙ ИММУНОПАТОГЕНЕТИК МЕХАНИЗМЛАРИ

ANNOTATSIIYA

Ревматоид артритда кuzatiladigan immunologik o'zgarishlar kasallikning rivojlanishi va progreslanish mexanizmlarini tushunishda muhim ahamiyatga ega. Ревматоид фактор (RF) va siklik sitrullinlangan peptidga qarshi antitanalar (anti-CCP) kabi autoantitanalar RA patogenezida asosiy rol o'ynab, yallig'lanish va bo'g'imlarning shikastlanishiga olib keladi. T-hujayralarning, ayniqsa proyallig'lanish subpopulyatsiyalarining disregulyatsiyasi ham RA da kuzatiladigan patologik immun javobni kuchaytiradi. RA da kuzatiladigan immunologik o'zgarishlar kasallikni oldini olish, erta tashxis qo'yish, davolash va prognozini baholashda muhim ahamiyat kasb etadi.

Kalit so'zlar: revmatoid artrit, autoantitanalar, patogenez, sitokinlar.

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by chronic inflammation of the synovial and eventual erosion of the joints, functional impairment, and a continuum of systemic manifestations. The Global Burden of Disease (GBD) project states that the highest age-standardized prevalence of RA is in the United States (0.38% -1 95-percent confidence interval [CI]: 0.36-0.40) and in Western Europe (0.35% -1 95-percent confidence interval [CI]: 0.31-0.38) [8]. Such epidemiologic results highlight the timeless applicability of RA in health sciences especially considering that it has a significant effect on the social and occupational capacity of patients [11].

Recent studies have significantly contributed to our understanding of the immunopathogenesis of RA with complex intricacy in crosstalk between innate and adaptive immune effectors. The immune dysregulation is central in the pathogenesis and maintenance of the disease and this requires a careful demarcation of the immunologic disturbances that cause this debilitating syndrome. In affected persons, the synovial structures are aberrantly attacked by the immune system and this triggers an evolutionary process that encompasses both the myeloid-derived cells and lymphocytes and finally coordinates the destruction of the joints [9].

The process of autoantibody identification and its examination, in particular, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), have transformed the process of RA diagnostics and prognostication. Not only these antibodies can be used as biomarkers but also they are directly involved in the pathogenic processes due to the formation of immune complexes and infiltration of the synovium. At the same time, it is now known that dysregulation of T-cell subsets including imbalance of Th1, Th2, Th17, and lack of regulatory T-cell (Treg) activity [14] are key players. Autoimmune loop is maintained by hyperactive T-cell responses and cytokine generation that promote synovial hyperplasia and unremitting destruction of the joints. The proposed study will examine and clarify the immunologic changes that support the pathogenesis of RA.

Pathogenesis of Rheumatoid Arthritis

The exact etiology of rheumatoid arthritis (RA) has been elucidated with a wide range of genetic, environmental and immunological factors largely agreeing to bring about its occurrence. Genetic predisposition is the most critical factor especially with certain human leukocyte antigen (HLA) alleles that carry the shared epitope of human leukocyte antigen-DRB1, which have been conclusively associated with an increased risk of RA [29]. Exposures to the environment such as tobacco smoke and some infectious agents have also been found to play a role in the triggering of RA in persons with a pre-existing genetic experience [12].

The typical feature of RA is chronic inflammation of the synovial membrane, which is manifested by synovitis and degeneration of the joints. Synovial inflammation is characterized by the presence of immune cells, in particular, lymphocytes, macrophages, and dendritic cells [28]. These cells trigger the release of pro-inflammatory cytokines that in turn maintain the inflammatory environment including

interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α) leading to further destruction of the joint. Repeated inflammatory processes result in synovial hyperplasia and growth, which results in the development of pannus. This pannus enters articular cartilage and eats underlying bone, thus causing permanent loss of joint and functional disability [31]. The inflammatory and tissue destruction cycle is also enhanced by the continuous erosion of joint components such as cartilage and bone that liberate other pro-inflammatory mediators.

In RA, it is an autoimmune process in the center of the action, whereby the elements of the synovial membrane are mistakenly identified as foreign by the host immune system. Two typical auto-antibodies, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), are essential in the pathogenesis of the disease. In the case of formation of immune complexes by these antibodies, they cause inflammatory reactions and complement cascades. The development of disease is controlled by complicated interactions between different kinds of immune cells- T cells, B cells and innate immune effectors. The dysregulation of the T-cell subsets that causes an imbalance between pro-inflammatory and anti-inflammatory cytokines promotes a pro-inflammatory state [30, 31, 34]. Comprehensive knowledge of such cell interactions is crucial to the successful regulation of immune reactions and prevention or reversal of inflammation and degeneration of the joints in RA.

The auto-antibody that is most commonly identified in RA is the rheumatoid factor (RF) which has been researched extensively. RF is a type of immunoglobulin M (IgM), and uncommonly, immunoglobulin G (IgG) antibody against the Fc of IgG [10]. RF may not be a disease-specific diagnostic marker of RA, but it is still a very prevalent one. High RF titres are associated with disease severity and damage to the joints. The other typical auto-antibody that is involved in RA is the anti-citrullinated protein antibody (ACPA). RF is regularly detected by serology through the use of enzyme-linked immunosorbent assay (ELISA) or latex agglutination. RF positivity is more common in diverse populations with the rates being higher in those patients who present the disease with more severe manifestations.

Role of Autoantibodies in Rheumatoid Arthritis

Auto-antibodies, especially, RF and ACPA are not only useful in diagnosis, but also significant in prognosis. RF is detected in about 70-80% in RA patients, but it can also be found in other autoimmune infectious disease states [8, 12]. By contrast, ACPA is very specific to RA, and it is able to be identified in approximately 60-70 percent of individuals, thus, is a dependable diagnostic tool [17]. These auto-antibodies when identified early help in the differentiation of RA and other arthritic conditions. Furthermore, their titres are associated with the disease activity and may predict the progression, damage of the joints and the chances of a successful therapeutic outcome [14, 20].

The auto-antibodies play a pathogenic role in RA, which is multifaceted. To begin with, RF and ACPA are capable of assembling immune complexes when attached to their cognate antigens IgG or citrullinated proteins. These complexes trigger complement pathways and initiate inflammatory reactions thus enhancing synovial

inflammation and joint damage [4]. Also, these auto-antibodies can enhance inflammatory processes in the synovial membrane itself. As an example, ACPA have been found to exist in the synovial tissue of RA patients and can bind citrullinated proteins directly with the encouragement of the generation of pro-inflammatory cytokines and chemokines in collaboration with resident synovial immune cells [26].

The auto-antibodies also mobilize and activate the immune effector cells (macrophages and neutrophils) in the synovial milieu. The binding of immune complexes/citrullinated proteins to these cells results in additional release of pro-inflammatory cytokines and degradative enzymes, and thus the continuance of the inflammatory process and destruction of the joints in the synovia [3]. Combined, these results highlight the importance of RF and ACPA in the pathogenesis of RA. Not only does it help in the diagnostic work-up but it has important clinical implications to disease prognosis and progression. These auto-antibodies mediate inflammation in the synovium through the mechanisms of immune-complex formation, complement activation, and through pro-inflammatory cascades. A thorough understanding of their roles offers to understand therapeutic points that can counter their harmful influences and prevent the development of the disease.

Dysregulation of T-Cell Regulation in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is characterized by a significant disturbance in the subpopulations of T-cells that results in the dysfunction of adaptive immune systems. Among them, T helper (Th) cells with a CD4+ positivity are one of the central organizers of the immune system, and they play a key role in the pathogenesis of RA [37]. Th subsets are also disproportionate in the arthritic environment; there is increased Th17 and a reduced quantity of regulatory T cells (Tregs) [16]. Th17 cells have pro-inflammatory effects using cytokines like interleukin -17 (IL -17), which increase inflammation of the synovium and destroyed joints. On the other hand, Tregs contain anti-inflammatory capability, keeping the immune-tolerant state by overseeing the overactivation of immune activities; their decrease in quantity or functionality may result in the ineffective suppression of the autoreactive lymphocytes to continue the autoimmune process and disease progression.

T cells invade the synovial membrane where they trigger resident macrophages and fibroblast-like synoviocytes transforming them into tissue-destructive effectors [19]. The pro-inflammatory Th17 Th17 subset, which produces IL-17, is the one believed to be one of the major causes of loss of tolerance to citrullinated self-proteins [13,15]. The autoimmune cascade is further enhanced by the tripartite costimulatory interaction between dendritic cells, T and B cells. The first inflammatory attacks happen in lymphoid tissues and joints and bring humoral factors and immune cells to the synovial fluid and create a pathogenic microenvironment that characterizes the RA pathogenesis [15].

The continuing imbalance between T17 and Treg enhances the lack of regulation of immunity, because a shrunken Treg compartment can no longer properly suppress the effects of inflammation. This creates a self-sustaining cycle of inflammation and leads to the ongoing damage of the joints and the development of the disease [19]. In addition, aberrant stimulation and pathophysiological changes of T cells in RA precondition the destruction of self-tolerance. T cells which have specificity to autoantigens are autoantigen-presenting cells that present citrullinated peptides and thereby perpetuate an autoimmune response of joint tissue. The sustained response of T cells with autoreactive properties leads to secretion of pro-inflammatory cytokines and chemokines, and attracts other immune effectors, and sustains synovial inflammation [30].

In addition to being an indicator of RA pathophysiology, Th17 cells are found in high density which correlates with other pathophysiological markers such as anti-citrullinated protein antibodies and C-reactive protein [36]. High levels of Th17 are linked to high levels in IL 21 and IL 23 as Th17 cells are reported to express a wide range of cytokines including IL 17A, IL 17F and IL 22 [13,15]. These agents trigger additional production of pro-inflammatory cytokines such as IL-1, IL-6, and TNF- α and prostaglandin E 2 (PGE 2) by the synovial fibroblasts and macrophages and enhance the level of inflammatory environment in the joint [38].

To summarize, T-cell homeostasis is dysregulated and decisively determines RA pathogenesis. The imbalance in Th subsets, the inadequacy of Treg cells and functions, and the abnormal activation of T-cells promotes chronic inflammation of the synovia and destruction of the joint. An in-depth insight into the processes of T-cell dysregulation provides a basis of specific therapeutic options that can help to restore the immune balance and prevent the development of the disease.

Dysregulation of B-Cell Regulation in Rheumatoid Arthritis

It is common knowledge that B lymphocytes represent an essential part of the adaptive system of the immune organism of the mammalian organism; however, in the case of rheumatoid arthritis (RA), they become the key players in the disease pathogenesis. Autoreactive B cells are the autoreactive B cells that identify self antigens and play a role in the destruction of host cells or tissues. In regular conditions, B cells that are autoreactive are destroyed at two major immune checkpoints: B-cell receptor (BCR) and a costimulatory signal. These two checkpoints are often breached in RA leading to massive accumulation of autoreactive mature naive B cells.

The initial activation of B cells is brought about by antigen interaction with BCR, and a costimulatory signal is needed to cross inhibitory checkpoints. The major mediators of these costimulatory signals are Toll-like receptors (TLRs) and CD40 that is expressed on B cells. The role played by the aberrant BCR signalling in the progression of autoreactive B cells in RA is central and this effect can be at least partially explained by mutations in PTPN22 (protein tyrosine phosphatase non-receptor type 22) which can modify BCR signalling pathways. Signaling defects of this peripheral checkpoint result in hindrance of T cell and B cell regulation and apoptosis.

There is evidence that blocking the B-cell activating factor (BAFF) and the proliferation-inducing ligand (APRIL) receptors decreases the levels of anti-collagen IgG in mice with collagen-induced arthritis (CIA), which eventuates the reduction of joint inflammation. In addition, the local production of cytokines (e.g., TNF-21, IL-12, IL-6, and IL-12) plays a significant role in inflammatory activity and cartilage and bone degradation. B cells and macrophages in the synovial fluid of people with RA produce IL-6; IL-6 enhances the differentiation of osteoclasts; therefore, joint destruction is strongly linked with the presence of IL-6 in the serum of people with RA the high levels of IL-6 are most often seen in the serum of patients with RA.

Memorial B cells (CD19 + CD27 +), tocilizumab is reported to improve clinical symptoms of RA patients to a considerable degree. Pro-inflammatory states are also sustained through the action of IL1 IL21 that promotes the proliferation and activation of B-cells. Therefore, IL-21 inhibition suppresses B-cell proliferation and differentiation caused by T-cells, and inflammation is suppressed.

Altogether, B cells are the key players in the pathogenesis and progression of rheumatoid arthritis by both producing autoantibodies and pro-inflammatory cytokines and by presenting antigens to T cells. TNF- α , IL-1 together with the receptor activator of nuclear factor kappa-B ligand (RANKL) stimulates osteoclastic activity and osteolysis in RA. In addition to this, TNF- α causes IL-1 release in synovial fibroblasts and macrophages. The B cell targeting is thus a good therapeutic approach to inhibit inflammation, pain and joint destruction in patients with RA. Continued studies on B-cell neuroscience and the contribution of autoantibodies to RA have potential application in the formulation of more effective and specific therapies of this disabling condition.

Innate Immune Responses in Rheumatoid Arthritis

The macrophages and dendritic cells (INAC) are a central part of the pathogenic cascade of rheumatoid arthritis (RA). The cells serve as major orchestrators of innate immunities and hence maintaining synovial inflammation and old age joint degradation. The macrophages concentrate in large masses in the synovial membrane, particularly in joints with RA. When activated, they release pro-inflammatory cytokines, including tumor necrosis factor 0 (TNF- α), interleukin 1 (IL-1), and interleukin 6 (IL-6). The resultant effect of these cytokines in turn increases the local inflammatory milieu, attracts other immune cells, angiogenesis and ultimately leads to the destruction of joints [13].

Dendritic cells (DCs) are well positioned in the synovial membrane where they act as effective antigen-presenting cells. Through the antigen introduction of T cells, DCs promote the process of autoreactive T cell activation and maintain the autoimmune response. Moreover, the DCs release pro-inflammatory cytokines, thus worsening the inflammatory condition of the synovial tissue [24]. Macrophages and dendritic cells working together generate a vast range of inflammatory mediators, such as TNF- α , IL-1, IL-6, IL-12, IL-23, and other chemokines, which mediate synovial inflammation and play a role in joint damage in RA.

TNF- α is one of the key players of inflammation in RA. Its synthesis by native immunity cells facilitates leukocytes recruitment, induces the production of other pro-inflammatory cytokines, and stimulates the growth of fibroblast-like synoviocytes, hence continuing to destroy joints [7]. IL-1 and IL-6, in turn, are pro-inflammatory cytokines that are produced by innate cells of the immune system. IL-1 triggers inflammatory reactions of the synovium, angiogenesis, and the synthesis of matrix metalloproteinases (MMPs), which contribute to the breakdown of the joints. The IL-6 stimulates B-cells activation, T-cells differentiation, and production of acute-phase reactants, which maintains the inflammatory cascade that is typical of RA [14].

Both IL-12 and IL-23 are released by innate immune cells and they are critical to T-cell activation and differentiation. These cytokines facilitate the emergence and sustenance of Th1 and Th17 cell reactions, which boost additional synovial infection and destruction of the joints in RA [27]. Innate immune cells also produce a number of different chemokines in RA, including CCL2, CCL3, CCL5, and CXCL8. These chemokines recruit and stimulate more immune cells to inflame site locations thus maintaining inflammatory processes and continuing inflammatory processes of the synovium [6].

The innate immune cells that prevail in inflammatory RA have resulted in the development of specific therapeutic interventions. Anti-TNF- α biologics such as adalimumab and etanercept have shown significant response in alleviating RA through counteracting the pro-inflammatory activity of TNF- α and decreasing the synovial inflammation as well as the joint erosion. Therefore, innate immune cells have become the focus of RA pathogenicity, and the production of

cytokines and chemokines by them, along with their communication with adaptive immune cells, determines the development of effective therapeutic strategies that should suppress synovial inflammation and prevent inflammatory damage to joints.

Conclusions. Overall, rheumatoid arthritis (RA) is a naturally complex autoimmune disease, which is characterized by chronic inflammation and progressive destruction of the joints. The immunological disruptions of RA provide vital information on the mechanisms that mediate the development and progression of the disease. As the leading contributors to RA pathogenesis, autoantibodies, in particular, rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, play a central role in the amplification of inflammatory processes and damage of the joints. Unchecked T-cell reactions, particularly those of pro-inflammatory groups also play a role in the pathology of immunopathology that is aberrant in RA. TNF- α , IL-1 and IL-6 are cytokines and chemokines that play the major role of triggering inflammation and synovial destruction of the joints.

The immunological changes that are related to RA have serious implications in terms of diagnosis, management and prognosis. Autoantibodies are useful diagnostic tools that aid in the distinction between RA and other arthritides and give prognostic data which feed on to severity of the disease and predicts sensitivity to treatment. Decent evaluation of the interplay between immune cells in the synovial membrane (macrophages, dendritic cells, fibroblast-like synoviocytes) may help in the development of specific desensitizing therapies that will break the vicious cycle of inflammation and destruction of joints. Immunomodulatory therapies, which include methotrexate and other disease-modifying antirheumatic drugs (DMARDs) have shown to be effective in reducing the disease activity. Further research on the immunopathological mechanisms that occur in RA is likely to promote the management of the patient and improve the clinical outcomes. Recent discoveries of individual autoantibody patterns, T-cell subset dysregulatory, and pathological cytokine profiles are promising therapeutic options and a better understanding of these immunological changes can help create individualized treatment protocols based on individual immune phenotype.

Список литературы / References/ Iqtiboslar:

1. Arkatkar T., Du S.W., Jacobs H.M., Dam E.M., Hou B., Buckner J.H., Rawlings D.J., Jackson S.W. B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity//*Journal of Experimental Medicine*, 2017, Vol. 214, No. 11, P. 3207-3217.
2. Bullock J., Rizvi S.A.A., Saleh A.M., Ahmed S.S., Do D.P., Ansari R.A., Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment//*Medical Principles and Practice*, 2018, Vol. 27, Rheumatoid Arthritis, No. 6, P. 501-507.
3. Chang M.H., Nigrovic P.A. Antibody-dependent and-independent mechanisms of inflammatory arthritis//*JCI insight*, 2019, Vol. 4, No. 5.
4. Derksen V., Huizinga T.W.J., Van Der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis//*Seminars in Immunopathology*. – Springer, 2017. – P. 437-446.
5. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., Mauri C. Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNF α Therapy//*The Journal of Experimental Medicine*, 2004, Vol. 200, No. 3, P. 277-285.
6. Elemam N.M., Hannawi S., Maghazachi A.A. Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis//*ImmunoTargets and Therapy*, 2020, Vol. Volume 9, P. 43-56.
7. Farrugia M., Baron B. The role of TNF- α in rheumatoid arthritis: a focus on regulatory T cells//*Journal of Clinical and Translational Research*, 2016, Vol. 2, The role of TNF- α in rheumatoid arthritis, No. 3, P. 84-90.
8. Finckh A., Gilbert B., Hodgkinson B., Bae S.-C., Thomas R., Deane K.D., Alpinar-Rodriguez D., Lauper K. Global epidemiology of rheumatoid arthritis//*Nature Reviews Rheumatology*, 2022, Vol. 18, No. 10, P. 591-602.
9. Guo Q., Wang Y., Xu D., Nossent J., Pavlos N.J., Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies//*Bone research*, 2018, Vol. 6, Rheumatoid arthritis, No. 1, P. 15.
10. Ingegnoli F., Castelli R., Gualtierotti R. Rheumatoid factors: clinical applications//*Disease markers*, 2013, Vol. 35, Rheumatoid factors, P. 727-734.
11. Karlson E.W., Deane K. Environmental and gene-environment interactions and risk of rheumatoid arthritis//*Rheumatic Disease Clinics of North America*, 2012, Vol. 38, No. 2, P. 405-426.
12. Kinne R.W., Bräuer R., Stuhlmüller B., Palombo-Kinne E., Burmester G.-R. [No title found]//*Arthritis Research*, 2000, Vol. 2, No. 3, P. 189.
13. Klak A., Raciborski F., Samel-Kowalik P. Social implications of rheumatic diseases//*Reumatologia/Rheumatology*, 2016, Vol. 54, No. 2, P. 73-78.
14. Kondo N., Kuroda T., Kobayashi D. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis//*International Journal of Molecular Sciences*, 2021, Vol. 22, No. 20, P. 10922.
15. Kotake S., Nanke Y., Yago T., Kawamoto M., Kobashigawa T., Yamanaka H. Ratio of circulating IFN γ +“Th17 cells” in memory Th cells is inversely correlated with the titer of anti-CCP antibodies in early-onset rheumatoid arthritis patients based on flow cytometry methods of the human immunology project//*BioMed Research International*, 2016, Vol. 2016.

16. Lee G.R. The balance of Th17 versus Treg cells in autoimmunity//International journal of molecular sciences, 2018, Vol. 19, No. 3, P. 730.
17. Liang Z., Wang N., Shang L., Wang Y., Feng M., Liu G., Gao C., Luo J. Evaluation of the immune feature of ACPA-negative rheumatoid arthritis and the clinical value of matrix metalloproteinase-3//Frontiers in Immunology, 2022, Vol. 13, P. 939265.
18. Malemud C.J. The role of the JAK/STAT signal pathway in rheumatoid arthritis//Therapeutic advances in musculoskeletal disease, 2018, Vol. 10, No. 5-6, P. 117-127.
19. Mellado M., Martinez-Munoz L., Cascio G., Lucas P., Pablos J.L., Rodríguez-Frade J.M. T cell migration in rheumatoid arthritis//Frontiers in immunology, 2015, Vol. 6, P. 384.
20. Moura R.A., Cascao R., Perpetuo I., Canhao H., Vieira-Sousa E., Mourao A.F., Rodrigues A.M., Polido-Pereira J., Queiroz M.V., Rosario H.S., Souto-Carneiro M.M., Graca L., Fonseca J.E. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival//Rheumatology, 2011, Vol. 50, No. 2, P. 278-282.
21. Rapetti L., Chavele K.-M., Evans C.M., Ehrenstein M.R. B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis//Annals of the Rheumatic Diseases, 2015, Vol. 74, No. 1, P. 294-302.
22. Rasmussen T.K., Andersen T., Hvid M., Hetland M.L., Hørslev-Petersen K., Stengaard-Pedersen K., Holm C.K., Deleuran B. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis//The Journal of rheumatology, 2010, Vol. 37, No. 10, P. 2014-2020.
23. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis//Bone, 2002, Vol. 30, No. 2, P. 340-346.
24. Santiago-Schwarz F., Anand P., Liu S., Carsons S.E. Dendritic Cells (DCs) in Rheumatoid Arthritis (RA): Progenitor Cells and Soluble Factors Contained in RA Synovial Fluid Yield a Subset of Myeloid DCs That Preferentially Activate Th1 Inflammatory-Type Responses//The Journal of Immunology, 2001, Vol. 167, Dendritic Cells (DCs) in Rheumatoid Arthritis (RA), No. 3, P. 1758-1768.
25. Scott L.J. Tocilizumab: A Review in Rheumatoid Arthritis//Drugs, 2017, Vol. 77, Tocilizumab, No. 17, P. 1865-1879.
26. Sokolova M.V., Schett G., Steffen U. Autoantibodies in rheumatoid arthritis: historical background and novel findings//Clinical Reviews in Allergy & Immunology, 2022, Autoantibodies in rheumatoid arthritis, P. 1-14.
27. Tang C., Chen S., Qian H., Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases//Immunology, 2012, Vol. 135, Interleukin-23, No. 2, P. 112-124.
28. Tran C.N., Lundy S.K., Fox D.A. Synovial biology and T cells in rheumatoid arthritis//Pathophysiology, 2005, Vol. 12, No. 3, P. 183-189.
29. Van Drongelen V., Holoshitz J. Human leukocyte antigen–disease associations in rheumatoid arthritis//Rheumatic Disease Clinics, 2017, Vol. 43, No. 3, P. 363-376.
30. Wang T., Li C. Transcriptional Regulation of CD4+ T Cell Differentiation in Experimentally Induced Arthritis and Rheumatoid Arthritis//Arthritis & rheumatology, 2018, Vol. 70, No. 5, P. 653-661.
31. Wehr P., Purvis H., Law S.C., Thomas R. Dendritic cells, T cells and their interaction in rheumatoid arthritis//Clinical & Experimental Immunology, 2019, Vol. 196, No. 1, P. 12-27.
32. Wei S.-T., Sun Y.-H., Zong S.-H., Xiang Y.-B. Serum levels of IL-6 and TNF-α may correlate with activity and severity of rheumatoid arthritis//Medical science monitor: international medical journal of experimental and clinical research, 2015, Vol. 21, P. 4030.
33. Wu H., Su S., Wu Y., Wu Y., Zhang Z., Chen Q. Nanoparticle-facilitated delivery of BAFF-R siRNA for B cell intervention and rheumatoid arthritis therapy//International Immunopharmacology, 2020, Vol. 88, P. 106933.
34. Wu Q., Zhou X., Huang D., Ji Y., Kang F. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro//Cellular Physiology and Biochemistry, 2017, Vol. 41, No. 4, P. 1360-1369.
35. Wysocki T., Olesińska M., Paradowska-Gorycka A. Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis—from research to clinical practice//Cells, 2020, Vol. 9, No. 5, P. 1127.
36. Yap HY, Tee SZ, Wong MM, Chow SK, Peh SC, Teow SY. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells. 2018 Oct 9;7(10):161.